Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
86
HLN Quote, Financials, Valuation and Earnings
Last price:
$11.20
Seasonality move
:
5.14%
Day range:
$11.08 - $11.22
52-week range:
$8.71 - $11.42
Dividend yield:
1.65%
P/E ratio:
23.30x
P/S ratio:
3.56x
P/B ratio:
1.97x
Volume:
7.8M
Avg. volume:
7.8M
1-year change:
13.18%
Market cap:
$49.7B
Revenue:
$14.4B
EPS (TTM):
$0.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HLN
Haleon Plc
|
$3.7B | $0.32 | 1.58% | 8.98% | $11.82 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -- | -- | -- |
|
SLNCF
Silence Therapeutics Plc
|
$1.6M | -$0.15 | 700.8% | -12.5% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HLN
Haleon Plc
|
$11.16 | $11.82 | $49.7B | 23.30x | $0.06 | 1.65% | 3.56x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$1.09 | $17.94 | $914.3K | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$2.08 | $104.00 | $8.7M | -- | $0.00 | 0% | -- |
|
OXBDF
Oxford Biomedica Plc
|
$11.34 | -- | $1.4B | -- | $0.00 | 0% | 6.15x |
|
SLNCF
Silence Therapeutics Plc
|
$1.60 | -- | $226.7M | -- | $0.00 | 0% | 112.71x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HLN
Haleon Plc
|
38.17% | -0.291 | -- | 0.75x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.310 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.482 | 0.95% | 4.03x |
|
OXBDF
Oxford Biomedica Plc
|
37.49% | 2.408 | -- | 1.99x |
|
SLNCF
Silence Therapeutics Plc
|
0.25% | 4.622 | 0.09% | 5.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HLN
Haleon Plc
|
$2B | $448.1M | 5.64% | 8.91% | 14.46% | $921M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -90.47% | -120.93% | -- | -- |
|
SLNCF
Silence Therapeutics Plc
|
-$20.5K | -$23.7M | -101.67% | -101.79% | -14881.13% | -$11M |
Haleon Plc vs. Competitors
-
Which has Higher Returns HLN or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon Plc55.38% $0.06 $32.9B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About HLN or BDRX?
Haleon Plc has a consensus price target of $11.82, signalling upside risk potential of 5.94%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 16216.63%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Haleon Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Haleon Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon Plc1 1 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is HLN or BDRX More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.469%.
-
Which is a Better Dividend Stock HLN or BDRX?
Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.65%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 41.96% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or BDRX?
Haleon Plc quarterly revenues are $3.5B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Haleon Plc's price-to-earnings ratio is 23.30x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.56x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon Plc3.56x 23.30x $3.5B $295.8M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns HLN or NCNA?
NuCana Plc has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon Plc55.38% $0.06 $32.9B NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About HLN or NCNA?
Haleon Plc has a consensus price target of $11.82, signalling upside risk potential of 5.94%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 999900%. Given that NuCana Plc has higher upside potential than Haleon Plc, analysts believe NuCana Plc is more attractive than Haleon Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon Plc1 1 0 NCNANuCana Plc0 1 0 -
Is HLN or NCNA More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.677, suggesting its more volatile than the S&P 500 by 67.66%.
-
Which is a Better Dividend Stock HLN or NCNA?
Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.65%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 41.96% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or NCNA?
Haleon Plc quarterly revenues are $3.5B, which are larger than NuCana Plc quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than NuCana Plc's net income of -$378.9K. Notably, Haleon Plc's price-to-earnings ratio is 23.30x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.56x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon Plc3.56x 23.30x $3.5B $295.8M NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns HLN or OXBDF?
Oxford Biomedica Plc has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat Oxford Biomedica Plc's return on equity of -120.93%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon Plc55.38% $0.06 $32.9B OXBDFOxford Biomedica Plc-- -- $140.3M -
What do Analysts Say About HLN or OXBDF?
Haleon Plc has a consensus price target of $11.82, signalling upside risk potential of 5.94%. On the other hand Oxford Biomedica Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Haleon Plc has higher upside potential than Oxford Biomedica Plc, analysts believe Haleon Plc is more attractive than Oxford Biomedica Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon Plc1 1 0 OXBDFOxford Biomedica Plc0 0 0 -
Is HLN or OXBDF More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oxford Biomedica Plc has a beta of 1.082, suggesting its more volatile than the S&P 500 by 8.226%.
-
Which is a Better Dividend Stock HLN or OXBDF?
Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.65%. Oxford Biomedica Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 41.96% of its earnings as a dividend. Oxford Biomedica Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or OXBDF?
Haleon Plc quarterly revenues are $3.5B, which are larger than Oxford Biomedica Plc quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than Oxford Biomedica Plc's net income of --. Notably, Haleon Plc's price-to-earnings ratio is 23.30x while Oxford Biomedica Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.56x versus 6.15x for Oxford Biomedica Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon Plc3.56x 23.30x $3.5B $295.8M OXBDFOxford Biomedica Plc6.15x -- -- --
-
Which has Higher Returns HLN or SLNCF?
Silence Therapeutics Plc has a net margin of 8.37% compared to Haleon Plc's net margin of -13181.13%. Haleon Plc's return on equity of 8.91% beat Silence Therapeutics Plc's return on equity of -101.79%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon Plc55.38% $0.06 $32.9B SLNCFSilence Therapeutics Plc-12.89% -$0.15 $74.2M -
What do Analysts Say About HLN or SLNCF?
Haleon Plc has a consensus price target of $11.82, signalling upside risk potential of 5.94%. On the other hand Silence Therapeutics Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Haleon Plc has higher upside potential than Silence Therapeutics Plc, analysts believe Haleon Plc is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon Plc1 1 0 SLNCFSilence Therapeutics Plc1 0 0 -
Is HLN or SLNCF More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Silence Therapeutics Plc has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.438%.
-
Which is a Better Dividend Stock HLN or SLNCF?
Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.65%. Silence Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 41.96% of its earnings as a dividend. Silence Therapeutics Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or SLNCF?
Haleon Plc quarterly revenues are $3.5B, which are larger than Silence Therapeutics Plc quarterly revenues of $159K. Haleon Plc's net income of $295.8M is higher than Silence Therapeutics Plc's net income of -$21M. Notably, Haleon Plc's price-to-earnings ratio is 23.30x while Silence Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.56x versus 112.71x for Silence Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon Plc3.56x 23.30x $3.5B $295.8M SLNCFSilence Therapeutics Plc112.71x -- $159K -$21M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
17
ICLR alert for Feb 13
ICON plc [ICLR] is up 16.75% over the past day.
Buy
67
CGNX alert for Feb 13
Cognex Corp. [CGNX] is up 0.97% over the past day.
Buy
77
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 2.78% over the past day.
